225Ac-DOTA-hTAB004

N/A

Report date: 2025/11/12 17:54:31

Base Information

Drug Name225Ac-DOTA-hTAB004
Drug Alias Name225Ac-DOTA-hTAB004
ClassificationRadiation-emitting products > Nuclides > Actinium > 225AcRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionAnti-MUC1
TargetsMucin-1
Therapy Area/IndicationsTriple Negative Breast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOncoTab IncInvicro Llc
China Registration ClassN/A

Develop Information

Active CompaniesOncoTab IncInvicro Llc
Inactive CompaniesN/A
Active IndicationsTriple Negative Breast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A